AAP
NBIX icon

Ardsley Advisory Partners’s Neurocrine Biosciences NBIX Stock Holding History

Ardsley Advisory Partners’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-7,500
Closed -$676K – 179
2019
Q3 		$676K Buy
+7,500
New +$701K 0.15% 77
2017
Q4 		– Sell
-97,500
Closed -$5.97M – 165
2017
Q3 		$5.97M Buy
97,500
+92,500
+1,850% +$4.88M 0.79% 45
2017
Q2 		$230K Buy
+5,000
New +$243K 0.04% 122

Other funds holding NBIX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Ardsley Advisory Partners's NBIX Position: Q4 2019 in Review

Ardsley Advisory Partners sold out of Neurocrine Biosciences (NBIX) in Q4 2019, closing a stake of 7,500 shares — an estimated $676K sold.

Ardsley Advisory Partners first reported a position in NBIX in Q2 2017 and held it in 3 quarters. The position peaked at $5.97M in Q3 2017. 392 funds tracked by Wall St. Rank hold NBIX as of Q4 2019.

  • Ardsley Advisory Partners reported no remaining Neurocrine Biosciences position as of Q4 2019 after selling out during the quarter.
  • Ardsley Advisory Partners sold 7,500 Neurocrine Biosciences shares in Q4 2019, an estimated $676K.
  • Ardsley Advisory Partners first reported a position in Neurocrine Biosciences in Q2 2017 and held it in 3 quarters.
  • Ardsley Advisory Partners's Neurocrine Biosciences position peaked at $5.97M in Q3 2017.
  • 392 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2019.

Based on Ardsley Advisory Partners's 13F filing for Q4 2019, filed 14 Feb 2020.